Business Context and Reporting Period
Company: Kiora Pharmaceuticals, Inc. (KPRX)
Filing Type: Form 8-K (Current Report)
Date of Report: October 13, 2022
Reporting Period: Specific event date of October 13, 2022.
Business Context: The Company is a biopharmaceutical entity listed on The Nasdaq Capital Market. This filing addresses a specific regulatory compliance event regarding its stock listing status.
Key Financial Metrics
This Form 8-K filing does not contain financial statements, revenue figures, profit data, cash flow metrics, debt levels, or liquidity ratios. The document is limited to reporting a corporate event regarding stock listing compliance.
Material Changes
Regulatory Status Change: On October 13, 2022, the Company received notice from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). This resolves a prior deficiency regarding the trading price of its common stock.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) confirming the restoration of compliance. No forward-looking guidance, financial outlook, or new risk factors are disclosed in this specific report.
Unusual Items: None reported beyond the resolution of the listing deficiency.
Investor Verification Checklist
- Verify the current trading price of KPRX to ensure continued compliance with Nasdaq minimum bid requirements.
- Review the attached Press Release (Exhibit 99.1) for any additional context regarding the compliance period.
- Check subsequent filings for any new notices from Nasdaq regarding other listing standards (e.g., market value of listed securities or shareholder equity).
- Confirm the Company's status as an "Emerging Growth Company" and its election regarding extended transition periods for accounting standards.